Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ESO-TX103
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ESO-TX103 is an investigational CAR-T cell therapy being developed by EsoBiotec for the treatment of solid tumors. It is currently in the discovery phase, with early research underway in Belgium. The therapy utilizes chimeric antigen receptor (CAR) technology to engineer T cells to target and destroy cancer cells within solid tumors. While specific molecular targets or antigens for ESO-TX103 have not been disclosed, it is part of a pipeline that leverages advanced cell engineering platforms designed by EsoBiotec[1][2][3].
- Other names
- ESO TX103
02
Targets
B7-H3
Beyond the preview
Go deeper on ESO-TX103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ESO-TX103.